Back to top

Mr. Hogg has been an Executive Director and the Chief Executive Officer of Hutchison China MediTech Limited (Chi-Med) since 2006.  He joined Hutchison China in 2000 and has since led all aspects of the creation, implementation and management of the Chi-Med’s strategy, business and listing.  This includes the creation of its start-up businesses, including Hutchison Medi Pharma (HMP) and the acquisition and operational integration of assets that led to the formation of Chi-Med’s China joint ventures.
Prior to joining Hutchison China, Mr. Hogg spent ten years with P&G starting in the US in Finance and then Brand Management in the Laundry and Cleaning Products Division.  Mr Hogg then moved to China to manage P&G's detergent business followed by a move to Brussels to run P&G's global bleach business.  Mr Hogg received a Bachelor's degree in Civil Engineering from the University of Edinburgh and an MBA from the University of Tennessee.

Back to top

Prior to joining HMP in 2005, Dr. Su spent fifteen years with Pfizer's US R&D organization.  Dr. Su delivered several high quality new drug candidates during his time with Pfizer, most recently as a director in the Medicinal Chemistry Department.  He received his Ph.D. and post-doctoral fellowship in Chemistry from Harvard University under the guidance of Nobel Laureate Professor E. J. Corey, and his Bachelor's degree in Chemistry from Fudan University in Shanghai, China.

Back to top

Dr. Zhang joined HMP in 2005, prior to which he spent eleven years in Pfizer's US R&D organization, where he was a director in the Pharmaceutical Sciences Division.  Prior to Pfizer, he spent four years at the Bristol-Myers Squibb Research Institute.  Dr. Zhang received his Ph.D. in Chemistry from the University of Texas at Austin and his Bachelor's degree in Chemistry from Peking University, China.

Back to top

Dr. Wei has over ten years of experience in the life sciences industry, focusing on R&D, investment and business development.  Dr. Wei is Senior Vice President and head of  business development at HMP.  Previously, Dr. Wei was the Deputy General Manager of Burrill China Group, where he led Burrill' s business activities related to the Greater China Area. Burrill is one of the largest life sciences venture capital funds, with close to $1billion under management.  Prior to joining Burrill, Dr. Wei worked for WI Harper Group (WIH) and oversaw its global life sciences investment activities.  Before WIH, Dr. Wei was a management consultant at McKinsey in its Shanghai office.  Dr. Wei has also conducted R&D in several leading research organizations, including at the Duke University Medical Center and the Chinese Academy of Sciences.  Dr. Wei has obtained a Ph.D. in Biochemistry from North Carolina State University.  He also holds an M.B.A. from Darden Business School, University of Virginia.

Back to top

Dr.Mu has over 15 years of clinical research and development experience focusing on oncology, having held senior medical and clinical leadership roles with some of the most prestigious global phamaceutical and biotech companies such as Roche, Biogen Idec and most recently, Genentech. His industrial experience spans over early to late stage development, and medical affair with cytotoxic agents, small molecules, and monoclonal antibodies for solid tumors and hematologic malignancies.  He was involved in the development of a number of successful oncology drugs including Xeloda^®, Abraxane^® and Avastin^®.  With significant operating and team leadership experience from organizations with diverse cultures and operating environments, Dr.Mu is well versed in managing complex cross-functional teams, dealing with the US FDA and regulatory authorities in Europe and Asia, and successfully bringing drug candidates through the development process to market.
Dr.Mu received his medical degree from West China University of Medical Sciences and his Ph.D. in Epidemiology from the University of Califomia at Berkeley.  Earlier in his career, Dr.Mu was a Senior Fellow at the Schools of Medicine of the University of Washington and the University of Califormia at San Francisco, where he conducted translational research on breast cancer and autoimmune diseases.  He also spent nearly two years at Procter & Gambles' s Kobe Technical Centre, where he was responsible for clinical research and human safety programs in Asia Pacific.

Back to top

Dr. Wu joined HMP in 2008 with 17 years of experience in drug discovery and development in the pharmaceutical and biotechnology industry.  His past positions include Senior Director of Pharmaceutical Sciences at Phenomix Corporation, a California based drug discovery and development company, Director of Pharmaceutical Development at Pfizer Global Research & Development in San Diego, California (formerly Agouron Pharmaceuticals), and Senior Scientist at Roche at its Palo Alto site.  Dr. Wu has led many development project teams and advanced numerous drug candidates into different phases of clinical development and commercialization including Sutent, a new blockbuster anti-cancer drug from Pfizer.  Dr. Wu received a Ph. D. degree from Hong Kong University, and an MBA degree from the University of California at Irvine.  He is the past Chairman and President of the Board of the Sino-American Biotechnology and Pharmaceutical Association.  He received a Colleague Recognition Award from Pfizer in 2003 for his work on the Sutent project, a Dean's Scholar Award from the University of California at Irvine in the same year, and a Leadership Award from the Sino-American Biotechnology and Pharmaceutical Association in 2008.  Dr. Wu was the recipient of an American Heart Association Fellowship in 1990.

Back to top

Prior to joining HMP, Mr. Lee had been working in healthcare investment banking in the United States and Europe since 1998.  Mr. Lee was a Vice President at Credit Suisse, a multinational financial services company with an extensive global healthcare practice.  Based in the New York and London offices of Credit Suisse, Mr. Lee was involved in the execution and origination of mergers, acquisitions, public and private financings, and corporate strategy for life science companies such as AstraZeneca, Bristol-Myers Squibb, Genzyme and Nanosphere, amongst others.  Mr. Lee also spent time with the Business Development department of Bristol-Myers Squibb, focused on in-licensing.
Mr. Lee received his Bachelor of Engineering in Biochemical Engineering with First Class Honors from University College London, where he was awarded a Dean's Commendation.  He also received a Master of Business Administration from the Massachusetts Institute of Technology, Sloan School of Management.

Back to top

Prior to joining HMP, Dr. Wang was a senior director and research advisor at Eli Lily and Company.  She has over seventeen years of drug discovery and development experience and was recognized for her contribution to the discovery of several drug candidates for the treatment of infectious diseases, cancer and inflammatory disorders, including the HCV protease inhibitor Incivek^® which launched in 2011.  Dr. Wang published more than fifty peer-reviewed papers and was credited as a co-inventor of numerous patents. Dr Wang obtained her Ph.D. from Purdue University, USA.

Back to top